Chemomab Therapeutics Unveils Significant Findings for PSC
Chemomab Therapeutics Ltd. (CMMB) recently made headlines with the announcement of its late-breaking abstract regarding the results of the Phase 2 SPRING trial designed to treat primary sclerosing cholangitis (PSC). This clinical stage biotechnology company is focused on developing innovative therapeutics that address fibro-inflammatory diseases, which often lack adequate treatment options.
Exciting Opportunity at AASLD The Liver Meeting® 2024
The much-anticipated findings from Chemomab will be presented at the prestigious American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024. This event is set to take place in San Diego, providing a platform for the latest advancements in liver disease research and treatment.
Presentation Details
Professor Christopher Bowlus, a notable figure in the field with his role as the Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine, will lead an oral presentation on the data from the SPRING trial. Attendees can look forward to learning how CM-101, Chemomab’s innovative monoclonal antibody, showed promise in improving fibrosis biomarkers in patients diagnosed with PSC.
Key Insights from the Phase 2 SPRING Trial
In the double-blinded portion of the Phase 2 SPRING trial, data indicated positive trends suggesting that CM-101 could significantly benefit patients suffering from this rare liver condition. During the presentation titled "CM-101 improved fibrosis biomarkers in patients with primary sclerosing cholangitis: The Phase 2 SPRING Study", critical insights will be shared about the efficacy and potential seen in the trial.
Abstract Publication Number
The abstract discussing these crucial findings is identified by Publication Number 5005 and will be part of the Late Breaking Abstract Parallel Session 1 at the conference. This showcases the significance of Chemomab's research at such a large gathering of experts focused on liver diseases.
Company Insights and Future Directions
Chemomab's continued dedication to tackling high unmet needs: The company has aligned its strategies to focus not only on PSC but also other severe fibro-inflammatory diseases. The promising results from their clinical trials for CM-101 have opened pathways for future studies, making it a crucial player in the biotechnology sector.
Upcoming Milestones
As Chemomab prepares for upcoming milestones in early 2025, they anticipate receiving FDA feedback regarding the design of a planned Phase 3 registrational trial. With CM-101 receiving both FDA and EMA Orphan Drug designations, there is excitement surrounding its potential impact.
Chemomab's Commitment to Innovation
Since its inception, Chemomab has been proactive in its approach to developing treatments that truly make a difference in patients' lives. The company remains highly focused on the unique role of soluble protein CCL24, which is pivotal in promoting both fibrosis and inflammation in affected individuals.
Meeting Chemomab Leadership
Members of the Chemomab senior leadership team will be present at the AASLD conference and are open to engaging with attendees. They are eager to share their vision and innovations while discussing the future of therapies for PSC and beyond.
About Chemomab Therapeutics
Chemomab Therapeutics is at the forefront of developing groundbreaking therapeutics for fibro-inflammatory diseases. The ongoing developments of CM-101 highlight their commitment to addressing significant medical needs through innovative science.
Contact Information
For further inquiries, media representatives, and potential investors can reach out to Barbara Lindheim, Consulting Vice President for Investor & Public Relations, at +1 917-355-9234. Chemomab is dedicated to transparency and fostering communication with the community.
Frequently Asked Questions
What is the primary focus of Chemomab Therapeutics?
Chemomab Therapeutics focuses on developing innovative treatments for fibro-inflammatory diseases with high unmet medical needs.
When and where will the findings from the Phase 2 SPRING trial be presented?
The findings will be presented at the AASLD The Liver Meeting® 2024, November 15-19 in San Diego.
Who will be presenting Chemomab's results?
Professor Christopher Bowlus will present the results of the Phase 2 SPRING trial.
What does CM-101 target in patients?
CM-101 is designed to neutralize CCL24, a protein implicated in fibrosis and inflammation in patients with PSC.
What future milestones can we expect from Chemomab?
Chemomab expects feedback from the FDA on the design of its planned Phase 3 registrational trial early in 2025.
